KARTEPE MANUFACTURING SITE
DEVA Holding Kartepe Manufacturing Sites, located on İzmit - Ankara highway, in Kocaeli Kartepe district, founded on an area of 32,000 m2, with a closed area of 16,500 m2, comprise of state-of-the-art buildings where sterile liquid drugs, empty medical vials, and colognes are manufactured.
 
 

Sterile Liquid Drug Manufacturing Unit

Sterile Liquid Ampoules for Injection, Sterile Liquid Vials for Injection, Sterile Liquid Lyophilized Vials for Injection, and Sterile Liquid Solution for Infusion in PE bottle, Sterile Liquid Eye Drop in PE bottle and Sterile Liquid Diluent Vial solutions by BFS (Blow-Fill-Seal) technology can be manufactured in Kartepe Sterile Liquid Drug Manufacturing Sites. 

In our sites, in which 48 million units were manufactured in 2016, a total of 52,5 mission units were manufactured in 2017, corresponding to approximately 9,37% increase in production.



 

Manufacture of Sterile Vials for Injection

 

In our site, in which a total of 33,3 million units of vials and 31,35 million solvent vials were manufactured in 2016, a total of 38,18 million units of vials and 32,22 million solvent vials were manufactured in 2017. The total number of single vials we manufactured in 2017 is 181 million.

There was a 25% increase in the total number of single vial we manufactured in 2017 compared with 2016.

 

Manufacture of Sterile Liquid Vials for Injection and Sterile Liquid Lyophilized Vials for Injection

 

On our production line for Sterile Liquid Vials for Injection and Sterile Liquid Lyophilized Vials for Injection, on which a total of 10.6 million units of vials were manufactured in 2016, 12 million units of vials were manufactured in 2017. 

Vial manufacture increased by approximately 13,60% in 2017, compared with 2016.

BFS-SVP Manufacture

 

On the BfS-SVP production line on which a total of 1,34 million units of production was achieved in 2016, the same amount, i.e. 1,33 million units in total were produced in 2017.



BFS-LVP Manufacture

 

On our BFS-LVP production line, on which a total of 2,8 million bottles were manufactured in 2016, a total of 979,172 bottles were manufactured in 2017. Also, the BFS-LVP line was decommissioned in 2017, and the current area was allocated as a reserve area for potential new investments in the future. 

Furthermore, our site, which was approved by the Ministry of Health, Ministry of Food, Agriculture and Livestock, and German Ministry of Health for (BFS - SVP and BFS - LVP lines) and by US FDA (the inspection performed by United States Food and Drug Administration only on sterile liquid vial and sterile liquid lyophilized vial production line) was inspected in 2017 also by the Ministry of Health, and Iraqi and Kenyan Health Authorities, and successfully passed these inspections.

Manufacture of Empty Medical Vials

 

Our empty medical vial manufacturing unit meets a substantial part of the market’s need as one of the three leading medical vial manufacturing companies in our country.

Our sites, which holds ISO 9001:2008 certificate, is audited by Thuringen on a periodical basis.

In our unit, which has been implementing ISO 9001 quality management system since 2001, production was maintained during 2017 with a total of nine production lines, two of which was put in operation during the last few years.

The number of empty vials we manufactured was 175,9 million in 2016, and 235,1 million in 2017.

Manufacture of Cologne:

 

In the unit where Bogazici Colognes, one of the bestselling brands in Turkey, are manufactured, products appealing to different sections of society such as 80º lemon cologne and lavender are being produced

Our production numbers for colognes was 3,55 million in 2016 and 3,6 million in 2017.

In Kartepe manufacturing site, year 2017 rate of capacity utilization was 82%.

 

Production Indicators

 

The total human and veterinary products manufactured in our manufacturing sites on a unit basis was 131.0 million units in 2014, 168.3 million units in 2015, 176.8 million units in 2016, and 184.7 million units in 2017.

And the total manufacturing value (drugs and other) was realized as 260.6 million TL in 2014, 325.8 million TL in 2015, 359.6 million TL in 2016, and 401.1 million TL in 2017.